Herz-Kreislauf-Klinik Bevensen AG
- Address
- Roemstedter Strasse 25, 29549 Bad Bevensen, Germany
Structural Heart Disease Research
The Herz‑Kreislauf‑Klinik Bevensen AG concentrates on Cardiovascular Diseases, testing innovative treatments to lower the incidence of serious heart, stroke, and vascular complications.
- Evaluation of the novel agent AZD0780 against placebo
- Measurement of composite cardiovascular outcomes (MACE‑PLUS)
- Focus on patients with high risk of atherosclerotic events
The goal is to expand therapeutic options for those suffering from Atherosclerotic Cardiovascular Disease and to reduce overall cardiovascular mortality.
Hypertension and Renal Protection Studies
The clinic investigates whether adding a SGLT2 inhibitor to standard antihypertensive regimens can further decrease major adverse cardiovascular and renal events.
- Combination therapy with SGLT2i and conventional blood‑pressure drugs
- Assessment of cardiovascular and renal outcome benefits
- Inclusion of participants with elevated blood‑pressure levels
These trials target individuals with Arterial Hypertension and aim to improve both heart health and kidney function beyond traditional treatment.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1AstraZeneca AB1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Herz-Kreislauf-Klinik Bevensen AG
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Levosimendan in Patients with Pulmonary Hypertension and HFpEF | Tenax Therapeutics Inc. | Phase III | Recruiting | May 2026 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 1 | Unknown | 2025-12-10 | 2025-12-10 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.